A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers

被引：0
|
作者：
Donghoon Shin
Yoon Jung Lee
Jihye Choi
Dahyoung Lee
Minjeong Park
Magdalena Petkova
机构：
[1] Samsung Bioepis Co.,Medical Affairs
[2] Ltd,Clinical Development
[3] Samsung Bioepis Co.,Biometrics
[4] Ltd,Clinical Bioanalysis
[5] Samsung Bioepis Co.,Clinical Pharmacology Unit
[6] Ltd,undefined
[7] Samsung Bioepis Co.,undefined
[8] Ltd,undefined
[9] SGS LSS,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2020年 / 86卷
关键词：
SB8; Bevacizumab; Biosimilar; Pharmacokinetics; Immunogenicity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：567 / 575
页数：8
相关论文
共 50 条
  • [31] A Phase I Study Comparing PF-06439535 (A Potential Biosimilar) with Bevacizumab
    Knight, Beverly
    Rassam, Danielle
    Liao, Shanmei
    Meng, Xu
    Ewesuedo, Reginald
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S548 - S548
  • [32] A randomized, double-blind, single-dose study to assess bioequivalence of MB02 biosimilar after manufacturing iteration and reference bevacizumab
    Schwabe, C.
    Cole, A.
    Espigares-Correa, A.
    Beydon, M. E.
    Florez-Igual, A.
    Queiruga-Parada, J.
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2023, 11 (02):
  • [33] A Phase I, Randomized, Double-blind, Single-dose Study to Evaluate the Biosimilarity of SB16 (Proposed Denosumab Biosimilar) with Reference Denosumab in Healthy Male Subjects
    Lee, Hyuna
    Kim, Sujung
    Seo, Hyoryeong
    Kim, Soyeon
    JOURNAL OF BONE AND MINERAL RESEARCH, 2023, 38 : 181 - 181
  • [34] Comparison of SB17 and reference ustekinumab in healthy adults: A randomized, double-blind, single-dose, phase I study
    Jeong, Hansol
    Kang, Taeseung
    Lee, Jiyoon
    Im, Seongsik
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2024, 62 (05) : 231 - 240
  • [35] A PHASE I PHARMACOKINETIC STUDY COMPARING SB4, AN ETANERCEPT BIOSIMILAR, AND ETANERCEPT REFERENCE PRODUCT (ENBREL®) IN HEALTHY MALE SUBJECTS
    Lee, Y. J.
    Shin, D.
    Kim, Y.
    Kang, J. W.
    Fuhr, R.
    Gauliard, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 718 - 718
  • [36] A phase III, randomized, double-blind, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB8 (proposed bevacizumab biosimilar) and reference bevacizumab in patients with metastatic or recurrent nonsquamous non-small cell lung cancer
    Reck, Martin
    Luft, Alexander
    Bondarenko, Igor
    Shevnia, Serhii
    Trukhin, Dmytro
    Kovalenko, Nadezhda, V
    Vacharadze, Kakha
    Andrea, Fulop
    Hontsa, Anatoliy
    Choi, Jihye
    Shin, Donghoon
    LUNG CANCER, 2020, 146 : 12 - 18
  • [37] A randomized phase I pharmacokinetic study comparing SB4 and etanercept reference product (Enbrel®) in healthy subjects
    Lee, Yoon Jung
    Shin, Donghoon
    Kim, Youngdoe
    Kang, Jungwon
    Gauliard, Anke
    Fuhr, Rainard
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 82 (01) : 64 - 73
  • [38] A Randomized, Phase I Pharmacokinetic Study Comparing SB2 and Infliximab Reference Product (Remicade®) in Healthy Subjects
    Shin, Donghoon
    Kim, Youngdoe
    Kim, Yoo Seok
    Koernicke, Thomas
    Fuhr, Rainard
    BIODRUGS, 2015, 29 (06) : 381 - 388
  • [39] A Randomized, Phase I Pharmacokinetic Study Comparing SB2 and Infliximab Reference Product (Remicade®) in Healthy Subjects
    Donghoon Shin
    Youngdoe Kim
    Yoo Seok Kim
    Thomas Körnicke
    Rainard Fuhr
    BioDrugs, 2015, 29 : 381 - 388
  • [40] A randomized Phase I pharmacokinetic trial comparing the potential biosimilar trastuzumab (SIBP-01) with the reference product (Herceptin®) in healthy Chinese male volunteers
    Zhou, Huan
    Cao, Shugang
    Zhu, Xingyu
    Xie, Jing
    Fan, Ling
    Ge, Qin
    Wang, Ying
    Zhu, Juan
    Liu, Yuanyuan
    Shao, ZhongHuan
    Shan, Rongfang
    Liu, Bingyan
    Wang, Hongju
    Ding, Li
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2020, 16 (10) : 997 - 1003
12345